HIV molecular immunology database

 

Search Antibody Database

Found 3 matching records:

Displaying record number 492

Download this epitope record as JSON.

MAb ID 5021
HXB2 Location gp160(310-316)
DNA(7152..7172)
gp160 Epitope Map
Author Location gp120
Epitope IQRGPGRA Epitope Alignment
IQRGPGRA epitope logo
Ab Type gp120 V3 // V3 glycan (V3g)
Neutralizing L
Species (Isotype) mouse(IgG)
Patient  
Immunogen vaccine
Keywords antibody generation, antibody interactions, binding affinity, novel epitope, optimal epitope

Vaccine Details

Vaccine type peptide
Vaccine strain B clade BH10
Vaccine component Env V3

Notes

Showing 2 of 2 notes.

References

Showing 4 of 4 references.

Durda1988 P. J. Durda, B. Leece, A. M. Jenoski, H. Rabin, A. Fisher, R. Gallo, and F. Wong-Staal. Characterization of Murine Monoclonal Antibodies to HIV-1 Induced by Synthetic Peptides. AIDS Res. Hum. Retroviruses, 4:331-342, 1988. PubMed ID: 2848556. Show all entries for this paper.

Durda1990 P. J. Durda, L. Bacheler, P. Clapham, A. M. Jenoski, B. Leece, T. J. Matthews, A. McKnight, R. Pomerantz, M. Rayner, and K. J. Weinhold. HIV-1 Neutralizing Monoclonal Antibodies Induced by a Synthetic Peptide. AIDS Res. Hum. Retroviruses, 6:1115, 1990. PubMed ID: 1702301. Show all entries for this paper.

Langedijk1991 J. P. M. Langedijk, N. K. T. Back, P. J. Durda, J. Goudsmit, and R. H. Meloen. Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1. J. Gen. Virol., 72:2519-2526, 1991. MAbs were raised against RIQRGPGRAFVTIGK by immunizing mice. Fine structure of MAb binding sites was mapped using pepscan. Preservation of the $\beta$ turn at the tip of the loop was critical. PubMed ID: 1919529. Show all entries for this paper.

Moore1993c J. P. Moore, M. Thali, B. A. Jameson, F. Vignaux, G. K. Lewis, S.-W. Poon, M. S. Fung, P. J. Durda, L. Akerblom, B. Wahren, D. D. Ho, Q. J. Sattentau, and J. Sodroski. Immunochemical Analysis of the gp120 Surface Glycoprotein of Human Immunodeficiency Virus Type 1: Probing the Structure of the C4 and V4 Domains and the Interaction of the C4 Domain with the V3 Loop. J. Virol., 73:4785-4796, 1993. General observations: C4 and V3 MAbs are sensitive to the way the epitopes are presented, and this sensitivity cannot be correlated to peptide binding. Some V3-C4 domain interaction was indicated based on mutation and interference studies. PubMed ID: 7687303. Show all entries for this paper.


Displaying record number 493

Download this epitope record as JSON.

MAb ID 5042
HXB2 Location gp160(310-316)
DNA(7152..7172)
gp160 Epitope Map
Author Location gp120
Epitope QRGPGRA Epitope Alignment
QRGPGRA epitope logo
Ab Type gp120 V3 // V3 glycan (V3g)
Neutralizing L
Species (Isotype) mouse
Patient  
Immunogen vaccine
Keywords  

Vaccine Details

Vaccine type peptide

Notes

Showing 1 of 1 note.

References

Showing 3 of 3 reference.

Durda1988 P. J. Durda, B. Leece, A. M. Jenoski, H. Rabin, A. Fisher, R. Gallo, and F. Wong-Staal. Characterization of Murine Monoclonal Antibodies to HIV-1 Induced by Synthetic Peptides. AIDS Res. Hum. Retroviruses, 4:331-342, 1988. PubMed ID: 2848556. Show all entries for this paper.

Durda1990 P. J. Durda, L. Bacheler, P. Clapham, A. M. Jenoski, B. Leece, T. J. Matthews, A. McKnight, R. Pomerantz, M. Rayner, and K. J. Weinhold. HIV-1 Neutralizing Monoclonal Antibodies Induced by a Synthetic Peptide. AIDS Res. Hum. Retroviruses, 6:1115, 1990. PubMed ID: 1702301. Show all entries for this paper.

Moore1993c J. P. Moore, M. Thali, B. A. Jameson, F. Vignaux, G. K. Lewis, S.-W. Poon, M. S. Fung, P. J. Durda, L. Akerblom, B. Wahren, D. D. Ho, Q. J. Sattentau, and J. Sodroski. Immunochemical Analysis of the gp120 Surface Glycoprotein of Human Immunodeficiency Virus Type 1: Probing the Structure of the C4 and V4 Domains and the Interaction of the C4 Domain with the V3 Loop. J. Virol., 73:4785-4796, 1993. General observations: C4 and V3 MAbs are sensitive to the way the epitopes are presented, and this sensitivity cannot be correlated to peptide binding. Some V3-C4 domain interaction was indicated based on mutation and interference studies. PubMed ID: 7687303. Show all entries for this paper.


Displaying record number 585

Download this epitope record as JSON.

MAb ID 450-D (450-D-3, 450D, 450)
HXB2 Location gp160(498-504)
DNA(7716..7736)
gp160 Epitope Map
Author Location gp120(475-486 BH10)
Research Contact Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
Epitope PTKAKRR Epitope Alignment
PTKAKRR epitope logo
Ab Type gp120 C5
Neutralizing  
Species (Isotype) human(IgG1λ)
Patient  
Immunogen HIV-1 infection
Keywords antibody binding site, antibody generation, dendritic cells, neutralization

Notes

Showing 15 of 15 notes.

References

Showing 16 of 16 references.

Isolation Paper
Karwowska1992 S. Karwowska, M. K. Gorny, A. Buchbinder, V. Gianakakos, C. Williams, T. Fuerst, and S. Zolla-Pazner. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res. Hum. Retroviruses, 8:1099-1106, 1992. A single linear MAb was generated, to the immunodominant domain in the C-terminal portion of gp120. This antibody did not inhibit rCD4-rgp120 binding or neutralize IIIB or MN. Three conformational epitope binding MAbs were also described in this paper that could neutralize IIIB and MN. PubMed ID: 1380257. Show all entries for this paper.

Cook1994 D. G. Cook, J. Fantini, S. L. Spitalnik, and F. Gonzalez-Scarano. Binding of Human Immunodeficiency Virus Type 1 HIV-1 gp120 to Galactosylceramide (GalCer): Relationship to the V3 Loop. Virol., 201:206-214, 1994. Antibodies against GalCer can block infection of CD4-negative cells from the brain and colon that are susceptible to HIV infection. This paper explores the ability of a panel of MAbs to inhibit binding of gp120 to GalCer, and also of the binding of GalCer to inhibit MAb-gp120 interaction. MAbs to the V3 loop and GalCer showed mutual inhibition of binding to gp120, and anti-CD4 binding site MAbs showed reduced inhibition. N- and C-terminal MAbs didn't influence GalCer binding. PubMed ID: 8184533. Show all entries for this paper.

Durda1988 P. J. Durda, B. Leece, A. M. Jenoski, H. Rabin, A. Fisher, R. Gallo, and F. Wong-Staal. Characterization of Murine Monoclonal Antibodies to HIV-1 Induced by Synthetic Peptides. AIDS Res. Hum. Retroviruses, 4:331-342, 1988. PubMed ID: 2848556. Show all entries for this paper.

Forthal1995 D. N. Forthal, G. Landucci, M. K. Gorny, S. Zolla-Pazner, and W. E. Robinson, Jr. Functional Activities of 20 Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Human Monoclonal Antibodies. AIDS Res. Hum. Retroviruses, 11:1095-1099, 1995. A series of tests were performed on 20 human monoclonal antibodies to assess their potential therapeutic utility. Antibodies were tested for potentially harmful complement-mediated antibody enhancing activity (C-ADE), and for potentially beneficial neutralizing activity and antibody dependent cellular cytotoxicity ADCC. PubMed ID: 8554906. Show all entries for this paper.

Gorny1994 M. K. Gorny, J. P. Moore, A. J. Conley, S. Karwowska, J. Sodroski, C. Williams, S. Burda, L. J. Boots, and S. Zolla-Pazner. Human Anti-V2 Monoclonal Antibody That Neutralizes Primary but Not Laboratory Isolates of Human Immunodeficiency Virus Type 1. J. Virol., 68:8312-8320, 1994. Detailed characterization of the MAb 697-D. PubMed ID: 7525987. Show all entries for this paper.

Hioe1997b C. E. Hioe, S. Xu, P. Chigurupati, S. Burda, C. Williams, M. K. Gorny, and S. Zolla-Pazner. Neutralization of HIV-1 Primary Isolates by Polyclonal and Monoclonal Human Antibodies. Int. Immunol., 9(9):1281-1290, Sep 1997. PubMed ID: 9310831. Show all entries for this paper.

Hioe2000 C. E. Hioe, G. J. Jones, A. D. Rees, S. Ratto-Kim, D. Birx, C. Munz, M. K. Gorny, M. Tuen, and S. Zolla-Pazner. Anti-CD4-Binding Domain Antibodies Complexed with HIV Type 1 Glycoprotein 120 Inhibit CD4+ T Cell-Proliferative Responses to Glycoprotein 120. AIDS Res. Hum. Retroviruses, 16:893-905, 2000. PubMed ID: 10875615. Show all entries for this paper.

Hioe2001 C. E. Hioe, M. Tuen, P. C. Chien, Jr., G. Jones, S. Ratto-Kim, P. J. Norris, W. J. Moretto, D. F. Nixon, M. K. Gorny, and S. Zolla-Pazner. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. J. Virol., 75(22):10950--7, Nov 2001. URL: http://jvi.asm.org/cgi/content/full/75/22/10950. PubMed ID: 11602735. Show all entries for this paper.

Holl2006 Vincent Holl, Maryse Peressin, Thomas Decoville, Sylvie Schmidt, Susan Zolla-Pazner, Anne-Marie Aubertin, and Christiane Moog. Nonneutralizing Antibodies Are Able To Inhibit Human Immunodeficiency Virus Type 1 Replication in Macrophages and Immature Dendritic Cells. J. Virol., 80(12):6177-6181, Jun 2006. PubMed ID: 16731957. Show all entries for this paper.

Karwowska1992a S. Karwowska, M. K. Gorny, A. Buchbinder, and S. Zolla-Pazner. Type-specific human monoclonal antibodies cross-react with the V3-loop of various HIV-1 isolates. Vaccines 92, :171-174, 1992. Editors: F. Brown, H. S. Ginsberg and R. Lerner, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Show all entries for this paper.

Laal1994 Suman Laal, Sherri Burda, Miroslav K. Gorny, Sylwia Karwowska, Aby Buchbinder, and Susan Zolla-Pazner. Synergistic Neutralization of Human Immunodeficiency Virus Type 1 by Combinations of Human Monoclonal Antibodies. J. Virol., 68(6):4001-4008, Jun 1994. PubMed ID: 7514683. Show all entries for this paper.

Li1997 A. Li, T. W. Baba, J. Sodroski, S. Zolla-Pazner, M. K. Gorny, J. Robinson, M. R. Posner, H. Katinger, C. F. Barbas III, D. R. Burton, T.-C. Chou, and R. M Ruprecht. Synergistic Neutralization of a Chimeric SIV/HIV Type 1 Virus with Combinations of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies or Hyperimmune Globulins. AIDS Res. Hum. Retroviruses, 13:647-656, 1997. Multiple combinations of MAbs were tested for their ability to synergize neutralization of a SHIV construct containing HIV IIIB env. All of the MAb combinations tried were synergistic, suggesting such combinations may be useful for passive immunotherapy or immunoprophylaxis. Because SHIV can replicate in rhesus macaques, such approaches can potentially be studied in an it in vivo monkey model. PubMed ID: 9168233. Show all entries for this paper.

Manca1995 F. Manca, D. Fenoglio, M. T. Valle, G. L. Pira, A. Kunkl, R. S. Balderas, R. G. Baccala, D. H. Kono, A. Ferraris, D. Saverino, F. Lancia, L. Lozzi, and A. N. Theofilopoulos. Human T helper cells specific for HIV reverse transcriptase: possible role in intrastructural help for HIV envelope-specific antibodies. Eur. J. Immunol., 25:1217-1223, 1995. PubMed ID: 7539750. Show all entries for this paper.

Spear1993 G. T. Spear, D. M. Takefman, B. L. Sullivan, A. L. Landay, and S. Zolla-Pazner. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J. Virol., 67:53-59, 1993. This study looked at the ability of 16 human MAbs to activate complement. MAbs directed against the V3 region could induce C3 deposition on infected cells and virolysis of free virus, but antibodies to the CD4BS and C-terminal region and two regions in gp41 could induce no complement mediated effects. Pre-treatment with sCD4 could increase complement-mediated effects of anti-gp41 MAbs, but decreased the complement-mediated effects of V3 MAbs. Anti-gp41 MAbs were able to affect IIIB but not MN virolysis, suggesting spontaneous shedding of gp120 on IIIB virions exposes gp41 epitopes. IgG isotype did not appear to have an effect on virolysis or C3 deposition. PubMed ID: 7677959. Show all entries for this paper.

Verrier2001 F. Verrier, A. Nadas, M. K. Gorny, and S. Zolla-Pazner. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J. Virol., 75(19):9177--86, Oct 2001. URL: http://jvi.asm.org/cgi/content/full/75/19/9177. PubMed ID: 11533181. Show all entries for this paper.

Visciano2008a Maria Luisa Visciano, Michael Tuen, Pei-de Chen, and Catarina E. Hioe. Antibodies to the CD4-Binding Site of HIV-1 gp120 Suppress gp120-Specific CD4 T Cell Response while Enhancing Antibody Response. Infect. Agent. Cancer., 3:11, 2008. PubMed ID: 18638381. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health